2020
Margin negative resection and pathologic downstaging with multiagent chemotherapy with or without radiotherapy in patients with localized pancreas cancer: A national cancer database analysis
Miccio JA, Talcott WJ, Patel T, Park HS, Cecchini M, Salem RR, Khan SA, Stein S, Kortmansky JS, Lacy J, Narang A, Herman J, Jabbour SK, Hallemeier CL, Johung K, Jethwa KR. Margin negative resection and pathologic downstaging with multiagent chemotherapy with or without radiotherapy in patients with localized pancreas cancer: A national cancer database analysis. Clinical And Translational Radiation Oncology 2020, 27: 15-23. PMID: 33392398, PMCID: PMC7772693, DOI: 10.1016/j.ctro.2020.12.003.Peer-Reviewed Original ResearchPancreatic ductal adenocarcinomaCT3-4 diseaseMargin-negative resectionR0 resectionNon-metastatic pancreatic ductal adenocarcinomaLocalized Pancreatic Ductal AdenocarcinomaNational Cancer Database AnalysisPre-operative RTMulti-agent chemotherapyNational Cancer DatabasePathologic complete responsePre-operative radiotherapyKaplan-Meier methodCox regression analysisMultivariable associateMultiagent chemotherapyNegative resectionPathologic responseComplete responseMeier methodCurative treatmentPancreas cancerFemale sexCancer DatabaseDuctal adenocarcinoma
2019
MORPHEUS: A phase Ib/II study platform evaluating the safety and clinical efficacy of cancer immunotherapy (CIT)–based combinations in gastrointestinal (GI) cancers.
Desai J, Kortmansky J, Segal N, Fakih M, Oh D, Kim K, Rahma O, Ko A, Chung H, Alsina M, Yeh K, Li S, Al-Sakaff N, Patel J, Barak H, Wang J, Zhang X, Bleul C, Cha E, Lee J. MORPHEUS: A phase Ib/II study platform evaluating the safety and clinical efficacy of cancer immunotherapy (CIT)–based combinations in gastrointestinal (GI) cancers. Journal Of Clinical Oncology 2019, 37: tps467-tps467. DOI: 10.1200/jco.2019.37.4_suppl.tps467.Peer-Reviewed Original ResearchPancreatic ductal adenocarcinomaII trialUnacceptable toxicityClinical benefitColorectal cancerSignificant survival benefitGastroesophageal junction cancerCancer immune responseImmune escape mechanismsMultiple tumor typesSingle control armPrimary endpointSecondary endpointsDurable responsesJunction cancerSurvival benefitTreatment armsClinical efficacyGastrointestinal cancerPT cohortCancer immunotherapyControl armDuctal adenocarcinomaImmune responseMinimal efficacy